Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitor in Patients With Chronic Myeloid Leukemia

Launched by NATIONAL TAIWAN UNIVERSITY HOSPITAL · Feb 17, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how to better monitor the levels of specific medications called tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia (CML). These medications are important for managing CML, but many patients struggle with taking them as prescribed, which can affect their treatment success. The researchers aim to develop methods to measure the concentration of four different TKIs in the blood and understand how factors like diet and other medications can influence their effectiveness. By doing this, they hope to enhance patient safety and improve treatment outcomes.

To participate in the trial, you need to be an adult (20 years or older) who is receiving or about to receive treatment with one of these TKIs at the National Taiwan University Hospital or Cancer Center. Participants will provide blood samples to help the researchers gather important data. Overall, this study aims to make drug monitoring a regular part of care, which could lead to more effective treatment for people living with CML.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Adult patients (≥ 20 year-old)
• • 2. Patients who meet the above criteria and have already initiated or are going to receive imatinib, dasatinib, nilotinib, or ponatinib treatment at National Taiwan University Hospital/National Taiwan University Cancer Center from September 2022 to December 2025
• Exclusion Criteria:
• • 1. Patients who are unable to cooperate with blood drawing
• • 2. Patients who have not submit the informed consent